Purification and biochemical characterization of the Mycobacterium tuberculosis β-ketoacyl-acyl carrier protein synthases KasA and KasB

被引:120
作者
Schaeffer, ML
Agnihotri, G
Volker, C
Kallender, H
Brennan, PJ
Lonsdale, JT
机构
[1] GlaxoSmithKline, Collegeville, PA 19426 USA
[2] Colorado State Univ, Dept Microbiol, Ft Collins, CO 80523 USA
关键词
D O I
10.1074/jbc.M108903200
中图分类号
Q5 [生物化学]; Q7 [分子生物学];
学科分类号
071010 ; 081704 ;
摘要
Mycolic acids are vital components of the Mycobacterium tuberculosis cell wall, and enzymes involved in their formation represent attractive targets for the discovery of novel anti-tuberculosis agents. Biosynthesis of the fatty acyl chains of mycolic acids involves two fatty acid synthetic systems, the multifunctional polypeptide fatty acid synthase I (FASI), which performs de novo fatty acid synthesis, and the dissociated FASII system, which consists of monofunctional enzymes, and acyl carrier protein (ACP) and elongates FASI products to long chain mycolic acid precursors. In this study, we present the initial characterization of purified KasA and KasB, two beta -ketoacyl-ACP synthase (KAS) enzymes of the M. tuberculosis FASII system. KasA and KasB were expressed in E. coli and purified by affinity chromatography. Both enzymes showed activity typical of bacterial KASs, condensing an acyl-ACP with malonyl-ACP. Consistent with the proposed role of FASII in mycolic acid synthesis, analysis of various acyl-ACP substrates indicated KasA and KasB had higher specificity for long chain acyl-ACPs containing at least 16 carbons. Activity of KasA and KasB increased with use of M. tuberculosis AcpM, suggesting that structural differences between AcpM and E. coli ACP may affect their recognition by the enzymes. Both enzymes were sensitive to KAS inhibitors cerulenin and thiolactomycin. These results represent important steps in characterizing KasA and KasB as targets for antimycobacterial drug discovery.
引用
收藏
页码:47029 / 47037
页数:9
相关论文
共 48 条
[1]  
[Anonymous], 1978, Atlas of protein sequence and structure
[2]  
AUSUBEL FM, 1991, CURRENT PROTOCOLS MO, V2
[3]   INHA, A GENE ENCODING A TARGET FOR ISONIAZID AND ETHIONAMIDE IN MYCOBACTERIUM-TUBERCULOSIS [J].
BANERJEE, A ;
DUBNAU, E ;
QUEMARD, A ;
BALASUBRAMANIAN, V ;
UM, KS ;
WILSON, T ;
COLLINS, D ;
DELISLE, G ;
JACOBS, WR .
SCIENCE, 1994, 263 (5144) :227-230
[4]   Interpreting cell wall 'virulence factors' of Mycobacterium tuberculosis [J].
Barry, CE .
TRENDS IN MICROBIOLOGY, 2001, 9 (05) :237-241
[5]   Mycolic acids: Structure, biosynthesis and physiological functions [J].
Barry, CE ;
Lee, RE ;
Mdluli, K ;
Sampson, AE ;
Schroeder, BG ;
Slayden, RA ;
Yuan, Y .
PROGRESS IN LIPID RESEARCH, 1998, 37 (2-3) :143-179
[7]  
Bloch K, 1975, Methods Enzymol, V35, P84, DOI 10.1016/0076-6879(75)35141-0
[8]   THE ENVELOPE OF MYCOBACTERIA [J].
BRENNAN, PJ ;
NIKAIDO, H .
ANNUAL REVIEW OF BIOCHEMISTRY, 1995, 64 :29-63
[9]  
Choi KH, 2000, J BIOL CHEM, V275, P28201
[10]   Deciphering the biology of Mycobacterium tuberculosis from the complete genome sequence [J].
Cole, ST ;
Brosch, R ;
Parkhill, J ;
Garnier, T ;
Churcher, C ;
Harris, D ;
Gordon, SV ;
Eiglmeier, K ;
Gas, S ;
Barry, CE ;
Tekaia, F ;
Badcock, K ;
Basham, D ;
Brown, D ;
Chillingworth, T ;
Connor, R ;
Davies, R ;
Devlin, K ;
Feltwell, T ;
Gentles, S ;
Hamlin, N ;
Holroyd, S ;
Hornby, T ;
Jagels, K ;
Krogh, A ;
McLean, J ;
Moule, S ;
Murphy, L ;
Oliver, K ;
Osborne, J ;
Quail, MA ;
Rajandream, MA ;
Rogers, J ;
Rutter, S ;
Seeger, K ;
Skelton, J ;
Squares, R ;
Squares, S ;
Sulston, JE ;
Taylor, K ;
Whitehead, S ;
Barrell, BG .
NATURE, 1998, 393 (6685) :537-+